vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and TIC Solutions, Inc. (TIC). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $508.3M, roughly 1.2× TIC Solutions, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs -9.3%, a 43.7% gap on every dollar of revenue.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
RPRX vs TIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $508.3M |
| Net Profit | $214.2M | $-47.2M |
| Gross Margin | — | 35.2% |
| Operating Margin | 62.4% | -3.8% |
| Net Margin | 34.4% | -9.3% |
| Revenue YoY | 4.8% | — |
| Net Profit YoY | 2.9% | — |
| EPS (diluted) | $0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $508.3M | ||
| Q3 25 | $609.3M | $473.9M | ||
| Q2 25 | $578.7M | $313.9M | ||
| Q1 25 | $568.2M | $234.2M | ||
| Q4 24 | $593.6M | — | ||
| Q3 24 | $564.7M | — | ||
| Q2 24 | $537.3M | — | ||
| Q1 24 | $568.0M | — |
| Q4 25 | $214.2M | $-47.2M | ||
| Q3 25 | $288.2M | $-13.9M | ||
| Q2 25 | $30.2M | $-233.0K | ||
| Q1 25 | $238.3M | $-25.8M | ||
| Q4 24 | $208.2M | — | ||
| Q3 24 | $544.0M | — | ||
| Q2 24 | $102.0M | — | ||
| Q1 24 | $4.8M | — |
| Q4 25 | — | 35.2% | ||
| Q3 25 | — | 32.2% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 18.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 62.4% | -3.8% | ||
| Q3 25 | 70.1% | -1.4% | ||
| Q2 25 | 36.3% | 5.8% | ||
| Q1 25 | 94.0% | -4.0% | ||
| Q4 24 | 60.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 50.2% | — | ||
| Q1 24 | -13.0% | — |
| Q4 25 | 34.4% | -9.3% | ||
| Q3 25 | 47.3% | -2.9% | ||
| Q2 25 | 5.2% | -0.1% | ||
| Q1 25 | 41.9% | -11.0% | ||
| Q4 24 | 35.1% | — | ||
| Q3 24 | 96.3% | — | ||
| Q2 24 | 19.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | $0.49 | — | ||
| Q3 25 | $0.67 | $-0.08 | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.55 | — | ||
| Q4 24 | $0.46 | — | ||
| Q3 24 | $1.21 | — | ||
| Q2 24 | $0.23 | — | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $439.5M |
| Total DebtLower is stronger | $9.0B | $1.6B |
| Stockholders' EquityBook value | $9.7B | $2.2B |
| Total Assets | $19.6B | $4.4B |
| Debt / EquityLower = less leverage | 0.92× | 0.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $439.5M | ||
| Q3 25 | $938.9M | $164.4M | ||
| Q2 25 | $631.9M | $130.1M | ||
| Q1 25 | $1.1B | $155.7M | ||
| Q4 24 | $929.0M | — | ||
| Q3 24 | $950.1M | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $843.0M | — |
| Q4 25 | $9.0B | $1.6B | ||
| Q3 25 | $8.9B | $1.6B | ||
| Q2 25 | $8.0B | $751.3M | ||
| Q1 25 | $7.6B | $752.4M | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $2.2B | ||
| Q3 25 | $9.6B | $2.0B | ||
| Q2 25 | $9.5B | $1.2B | ||
| Q1 25 | $9.8B | $1.1B | ||
| Q4 24 | $10.3B | — | ||
| Q3 24 | $10.3B | — | ||
| Q2 24 | $9.8B | — | ||
| Q1 24 | $9.9B | — |
| Q4 25 | $19.6B | $4.4B | ||
| Q3 25 | $19.3B | $4.2B | ||
| Q2 25 | $18.3B | $2.2B | ||
| Q1 25 | $17.6B | $2.2B | ||
| Q4 24 | $18.2B | — | ||
| Q3 24 | $18.0B | — | ||
| Q2 24 | $17.7B | — | ||
| Q1 24 | $16.1B | — |
| Q4 25 | 0.92× | 0.74× | ||
| Q3 25 | 0.93× | 0.83× | ||
| Q2 25 | 0.84× | 0.64× | ||
| Q1 25 | 0.78× | 0.67× | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $49.7M |
| Free Cash FlowOCF − Capex | — | $37.1M |
| FCF MarginFCF / Revenue | — | 7.3% |
| Capex IntensityCapex / Revenue | — | 2.5% |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $61.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $49.7M | ||
| Q3 25 | $702.6M | $19.0M | ||
| Q2 25 | $364.0M | $-6.5M | ||
| Q1 25 | $596.1M | $32.8M | ||
| Q4 24 | $742.5M | — | ||
| Q3 24 | $703.6M | — | ||
| Q2 24 | $658.2M | — | ||
| Q1 24 | $664.6M | — |
| Q4 25 | — | $37.1M | ||
| Q3 25 | — | $10.3M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $28.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 7.3% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | -4.6% | ||
| Q1 25 | — | 12.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 2.5% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | — | ||
| Q2 25 | 12.06× | — | ||
| Q1 25 | 2.50× | — | ||
| Q4 24 | 3.57× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 6.45× | — | ||
| Q1 24 | 139.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
TIC
| Consulting Engineering Segment | $300.1M | 59% |
| Geospatial Segment | $131.3M | 26% |
| Fixed Unit Price Contracts | $54.3M | 11% |
| Other | $22.6M | 4% |
